PRNewsWire
14 Oct 2026, 02:17 UTC · 2h ago
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
Impact · against what's priced in
The failure of the axatilimab trial in IPF is already reflected in the immediate double-digit stock price drop. However, the subsequent announcement of a securities law investigation introduces new legal risk and potential settlement costs that could create a multi-quarter overhang on the stock.
- SNDX−0.30
No priced-in read yet





